<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01933204</url>
  </required_header>
  <id_info>
    <org_study_id>2012BAI24B01</org_study_id>
    <nct_id>NCT01933204</nct_id>
  </id_info>
  <brief_title>Acupuncture for Relieving Perimenopausal Symptoms</brief_title>
  <official_title>Acupuncture for Relieving Perimenopausal Symptoms: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu First people's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chengdu University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether acupuncture is effective for relieving
      perimenopausal symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A randomised controlled trial with superiority design

        -  A total of 220 participants will be included in 3 centers

        -  2 arms: acupuncture group and ClimenÂ® group
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Menopause Rating Scale</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The scale was developed and validated over the years from a research network of many institutions such as Organon Germany, Infratest Munich, Universities of Muenster and Berlin,the Berlin Center for Epidemiology and Health Research, etc. It is a scale consisted of 11 items, ranging from no symptoms to very severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menopausal Specific Quality of Life Questionnaire</measure>
    <time_frame>asessed 0, 6, 12, 24, 36 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Menopausal Specific Quality of Life Questionnaire (MENQOL) is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average hot flash score during 24 hours</measure>
    <time_frame>0, 12, 24, 36 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Estradiol in serum</measure>
    <time_frame>0, 12, 24 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of follicle stimulating hormone in serum</measure>
    <time_frame>0, 12, 24 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of luteinizing hormone in serum</measure>
    <time_frame>0, 12, 24 weeks after randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Perimenopause</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Climen 21 Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Climen 21 Tablets</intervention_name>
    <description>Climen Tablets are commonly used for menopausal symptoms</description>
    <arm_group_label>Climen 21 Tablets</arm_group_label>
    <other_name>Climen Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who complained of irregular menstrual cycle in the past 12 months, with
             a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during
             the past 12 months, or reported menopause for at least 60 days.

          -  Reported relative perimenopausal symptoms, e.g., hot flash, insomnia, migraine, easy
             irritation, etc.

          -  Age 40-50 years.

          -  Not accompanied with conditions that are needed for hormone therapy, e.g., menopause
             after surgery, active osteoporosis.

          -  Willing to participate and signing the inform consent.

        Exclusion Criteria:

          -  Had a regular menopausal cycle 3 months before this trial.

          -  Taking estrogen, selective serotonin reuptake inhibitor(SSRI), soy isoflavone,
             progesterone, Vitamin E or black cohosh in the 4 weeks before inclusion.

          -  receiving chemoradiotherapy.

          -  Agnogenic vaginal bleeding.

          -  Coagulation defeats, or taking anticoagulant drugs, such as warfarin, heparin, etc.

          -  Dermal diseases, e.g., eczema, psoriasis.

          -  Liver or kidney failure.

          -  Uncontrollable hypertension, diabetes, or thyroid diseases.

          -  With diabetic neuropathy, malignant cancer and mental diseases (including
             depression).

          -  Intend to gestation, in gestation period or lactation period.

          -  Using sedative or antianxiety drugs.

          -  With smoking or intemperance problems.

          -  Using cardiac pacemaker, or joint prosthesis.

          -  Low compliance.

          -  Benign tumor in breast.

          -  Family history of breast cancer.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chengdu University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erqi Qin, Master</last_name>
    <phone>028-66875871</phone>
    <email>qinerqi@foxmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chengdu University of Traditional Chinese Medicine</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610075</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erqi Qin, Master</last_name>
      <phone>028-66875871</phone>
      <email>qinerqi@foxmail.com</email>
    </contact>
    <investigator>
      <last_name>Hui Zheng, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First affiliated hospital of Chengdu University of TCM</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610075</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Er-qi Qin, MD</last_name>
      <phone>028-66875871</phone>
      <email>qinerqi@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>September 2, 2013</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perimenopause</keyword>
  <keyword>hot flash</keyword>
  <keyword>palpitation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
